About Baird Capital

• Founded: 1988

• Headquarters: Milwaukee, Wisconsin, United States

• AUM: Approximately $5bn across private equity and venture capital strategies (as of 2024)

• Strategy: Middle-market buyout and growth equity, focusing on healthcare, industrial, and technology sectors in North America and Europe

• Track record: Prior funds include Baird Capital Partners VIII ($1.3bn, 2021) and several sector-focused vehicles; maintains separate healthcare and industrial investment teams

• Leadership: Managing directors include Joe Azrack and Andrew Stec, among a multi-partner structure across offices in Milwaukee, London, and Chicago

Baird Capital closed the $450m continuation vehicle for Blue Matter Consulting, a life sciences consultancy the firm originally backed in 2020. The structure allows existing investors to roll forward or exit while bringing in new limited partners. Blue Matter advises pharmaceutical and biotech companies on commercial strategy, market access, and product launches.

Continuation funds in healthcare services are multiplying as GPs navigate a high-rate exit market where trade buyers remain cautious and IPO windows stay narrow. Baird's structure mirrors the $520m continuation vehicle Audax Group closed in late 2023 for healthcare IT portfolio company MedBridge, which also originated from a 2020-vintage fund. Both deals reflect a similar calculus: assets with defensible revenue streams but exit timelines pushed beyond the original fund's natural horizon.

The Blue Matter vehicle's $450m scale — roughly 35% of Baird's most recent flagship fund — signals the firm expects meaningful value creation runway remains. Watch whether Baird deploys follow-on capital for Blue Matter's geographic expansion or M&A, and how the continuation vehicle's economics compare to the 2020 entry basis. If the GP retained significant equity rather than crystalizing carry, that's a tell on conviction versus liquidity management.

Source: AltAssets